---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-04T10:31:18.257915'
end_time: '2025-12-04T10:39:01.007021'
duration_seconds: 462.75
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: FN3K
  gene_symbol: FN3K
  uniprot_accession: Q9H479
  protein_description: 'RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445};
    EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName:
    Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine
    3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};'
  gene_info: Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the fructosamine kinase family. .
  protein_domains: Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009);
    Fructosamin_kin (PF03881)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 36
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H479
- **Protein Description:** RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445}; EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName: Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine 3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};
- **Gene Information:** Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the fructosamine kinase family. .
- **Key Domains:** Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009); Fructosamin_kin (PF03881)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FN3K" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FN3K' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FN3K** (gene ID: FN3K, UniProt: Q9H479) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H479
- **Protein Description:** RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445}; EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName: Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine 3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};
- **Gene Information:** Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the fructosamine kinase family. .
- **Key Domains:** Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009); Fructosamin_kin (PF03881)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FN3K" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FN3K' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FN3K** (gene ID: FN3K, UniProt: Q9H479) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification
We verified the target as human FN3K (UniProt Q9H479), fructosamine-3-kinase, a protein kinase–like (PKL) fold enzyme in the fructosamine kinase family. Recent structural and mechanistic studies explicitly characterize human FN3K (HsFN3K) and distinguish it from its paralog FN3KRP, with organism Homo sapiens (human) confirmed (PDBs 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO) (garg2025themolecularbasis pages 12-13). Redox regulation is a conserved feature in the FN3K family (shrestha2020aredoxactiveswitch pages 1-2).

Comprehensive research report
1) Key concepts and definitions
- Gene/protein identity and family: FN3K encodes fructosamine-3-kinase, a conserved repair enzyme that adopts the protein kinase–like fold. FN3Ks are evolutionarily related to eukaryotic protein kinases and phosphorylate sugars attached to lysine residues in proteins (ketosamines/fructosamines), reversing early glycation damage (deglycation) (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; published Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2). Human structural work (Nature Communications, 2025) confirms canonical kinase features and substrate-binding elements (URL: https://doi.org/10.1038/s41467-025-56207-z; published Jan 6, 2025) (garg2025themolecularbasis pages 12-13, garg2025themolecularbasis pages 1-2).
- Primary enzymatic reaction (deglycation): FN3K transfers the γ-phosphate of ATP to the 3′-hydroxyl of the fructose-lysine (Amadori) moiety on glycated lysines. The fructosamine-3-phosphate is unstable and decomposes to release inorganic phosphate and the dicarbonyl 3-deoxyglucosone, regenerating the free lysine (Nature Communications 2025; URL above) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). Foundational descriptions of ketosamine/fructosamine phosphorylation and 3-deoxyglucosone formation are consistent with multi-omics reviews (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; published Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71).
- Substrate scope: HsFN3K reverses protein glycation by site-specific phosphorylation of fructose-lysine; activity on a small-molecule mimic (1-deoxy-1-morpholino-D-fructose, DMF) is robust. The paralog FN3KRP in mammals is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines, underscoring substrate differences within the family (supported by structural/mechanistic reviews and ancestral reconstruction analysis; bioRxiv, 2025; URL: https://doi.org/10.1101/2025.07.30.667714; posted Jul 30, 2025) (garg2025themolecularbasis pages 1-2, matlack2025ancestralproteinreconstruction pages 15-18, shrestha2023elucidatingtheunderstudied pages 90-95).

2) Recent developments and latest research (2023–2024 priority)
- Human FN3K structures and mechanism: Multiple human FN3K crystal structures were determined (apo and with nucleotide/sugar mimics), revealing features important for substrate recognition and catalysis and providing a framework for inhibitor design (Nature Communications, 2025; PDB: 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 2025) (garg2025themolecularbasis pages 12-13, garg2025themolecularbasis pages 1-2).
- Multi-omics pathway links: An FN3K CRISPR KO in human HepG2 cells, integrated with transcriptomics, metabolomics, and interactomics, connected FN3K to oxidative stress response, lipid biosynthesis (cholesterol and fatty acids), and carbon/co-factor metabolism. The study reports mitochondrial localization and enrichment of NAD-binding proteins, with experimental evidence that HsFN3K binds NAD compounds in a metal- and concentration-dependent manner (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).
- Redox regulation: A conserved redox-active “disulfide switch” centered on a P-loop cysteine regulates FN3K activity and oligomerization; reduction activates the enzyme. This mechanism was defined structurally in Arabidopsis FN3K and functionally extends to human FN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2). The redox model and metabolic feedback were further explored in 2023 analyses (shrestha2023elucidatingtheunderstudied pages 45-51).
- Cancer biology and FN3K–NRF2 axis: Computational and cellular studies suggest FN3K modulates NRF2-driven antioxidant signaling. Drug screens in breast cancer cells showed several approved anticancer drugs alter FN3K expression and NRF2 signaling (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). In renal cell carcinoma, amiloride reduced FN3K expression and restored sunitinib sensitivity; FN3K appeared to interact with VEGFR2 (iScience, 2024; URL: https://doi.org/10.1016/j.isci.2024.109997; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).

3) Current applications and real-world implementations
- Ex vivo tissue deglycation: Combined enzymatic treatment with FN3K and fructosyl-amino acid oxidase (FAOD) reduced AGE-associated autofluorescence in human skin specimens. FN3K or FAOD alone decreased AF by ~31–33%, while the combination achieved a 43% decrease; hypertrophic scar elasticity improved after FN3K treatment (International Journal of Molecular Sciences, 2023; URL: https://doi.org/10.3390/ijms24108981; May 15, 2023) (decker2023enzymaticdeglycationof pages 4-7).
- Therapeutic exploration: Computational screens and repurposing efforts have sought FN3K inhibitors/modulators, motivated by putative roles in redox homeostasis and cancer resistance (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). Restoration of TKI sensitivity in RCC via reducing FN3K expression (amiloride) illustrates a potential translational angle (iScience, 2024; URL above; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).

4) Expert opinions and analysis from authoritative sources
- Structural enzymology and regulation: The Science Signaling study articulates a generalizable redox regulatory mechanism in the FN3K family with clear evolutionary support and structural basis, expanding the regulatory repertoire of the kinase superfamily (AAAS journal; 2020) (shrestha2020aredoxactiveswitch pages 1-2). The Nature Communications human structural series provides high-resolution mechanistic insights enabling rational inhibitor design (2025; Springer Nature) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13).
- Systems-level function: The NPJ Systems Biology & Applications study (Nature Portfolio) integrates multi-omics to position FN3K within redox, lipid, and NAD-linked metabolic networks, arguing for mitochondrial association and NAD interactions as potential mechanisms connecting deglycation to metabolism (2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).

5) Relevant statistics and data (recent studies)
- Structural/biochemical metrics (human): HsFN3K forms redox-sensitive dimer/monomer species; a dimeric species exhibited ~60% higher kinase activity on a small-molecule fructosamine mimic (DMF) than monomer; both had similar Tm (~54 °C). Dimer converted to monomer under reducing conditions within ~20 min (Nature Communications, 2025; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 6, 2025) (garg2025themolecularbasis pages 1-2).
- Redox activation (plant ortholog): Reduction of intermolecular disulfides in AtFN3K activated the enzyme (>40-fold), implicating a conserved redox switch that is present in human FN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2, shrestha2023elucidatingtheunderstudied pages 45-51).
- Ex vivo skin deglycation: Average AF decrease following treatment was 31% with FN3K, 33% with FAOD, and 43% with combined FN3K+FAOD; scar elasticity improved after FN3K (IJMS, 2023; URL: https://doi.org/10.3390/ijms24108981; May 15, 2023) (decker2023enzymaticdeglycationof pages 4-7).
- Genetic associations with HbA1c and related traits: Open Targets collates strong genetic association evidence linking FN3K (and FN3KRP) loci to HbA1c measurement and related hematologic traits, with FN3K showing a high association score for “HbA1c measurement” (EFO_0004541) based on GWAS credible sets (Open Targets Platform; accessed 2025; see evidence PMIDs in platform record) (OpenTargets Search: -FN3K). A 2024 GWAS-based cFDR analysis highlights rs1046896 in FN3KRP as an HbA1c-associated pleiotropic locus (Biomedicines, 2024; URL: https://doi.org/10.3390/biomedicines12010157; Jan 8, 2024) (cheng2024sharedgeneticsbetween pages 4-5, cheng2024sharedgeneticsbetween pages 5-7).

Function, substrates, and specificity (focused annotation)
- Reaction and products: HsFN3K phosphorylates the O3′ position of fructose-lysine (Amadori) groups on glycated proteins, forming fructosamine-3-phosphate that decomposes to release phosphate and 3-deoxyglucosone, thereby restoring unmodified lysine and reversing early glycation (Nature Communications 2025; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 6, 2025) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). Multi-omics reviews concur and emphasize that 3-deoxyglucosone may affect cellular redox, implying feedback onto FN3K regulation (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71).
- Substrate class: HsFN3K acts on protein-bound fructosamines and also phosphorylates small-molecule fructosamine mimics (e.g., DMF) used for mechanistic/structural studies (Nature Communications, 2025; URL above) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). In contrast, the mammalian paralog FN3KRP displays ketosamine preference (ribulosamines/psicosamines), not fructosamines, consistent with ancestral and comparative analyses (bioRxiv, 2025; URL: https://doi.org/10.1101/2025.07.30.667714; Jul 30, 2025; and curated reviews) (matlack2025ancestralproteinreconstruction pages 15-18, shrestha2023elucidatingtheunderstudied pages 90-95).

Localization and regulation
- Subcellular localization: Human FN3K has been localized to mitochondria in human cells in a multi-omics context; presence in erythrocytes and serum is also reported (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 45-51).
- Redox-sensitive control: A conserved P-loop cysteine forms an intermolecular disulfide in an inhibited dimeric state; reduction breaks the disulfide, activates the kinase, and shifts oligomerization. This redox switch is well supported structurally in AtFN3K and functionally conserved in HsFN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2, shrestha2023elucidatingtheunderstudied pages 45-51). Human structural work shows redox-sensitive dimer/monomer states with differential activity (Nature Communications, 2025; URL above) (garg2025themolecularbasis pages 1-2).
- NAD compound binding: Multi-omics and biochemistry indicate HsFN3K specifically binds NAD compounds in a metal- and concentration-dependent manner, suggesting a link to NAD-mediated energy metabolism and redox balance (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).

Pathways and interactors
- NRF2 axis: FN3K-mediated deglycation has been linked to maintaining NRF2 function; computational and cell-based studies show modulation of FN3K alters NRF2-driven antioxidant signaling (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). Systems studies position FN3K within oxidative stress and lipid/co-factor metabolism pathways (NPJ Systems Biology & Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3).
- VEGFR2 in RCC: In renal cell carcinoma models, FN3K expression affected sunitinib response; evidence of interaction with VEGFR2 was presented, though VEGFR2 deglycation was not definitively proven (iScience, 2024; URL: https://doi.org/10.1016/j.isci.2024.109997; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).

Disease relevance and genetics
- Glycemic traits and HbA1c: Strong GWAS-based evidence links the FN3K/FN3KRP locus to HbA1c and related traits. Open Targets aggregates multiple GWAS credible-set evidences supporting FN3K association with “HbA1c measurement” (EFO_0004541) (Open Targets Platform; accessed 2025) (OpenTargets Search: -FN3K). A 2024 cFDR GWAS analysis highlights rs1046896 in FN3KRP as highly associated with HbA1c (Biomedicines, 2024; URL: https://doi.org/10.3390/biomedicines12010157; Jan 8, 2024) (cheng2024sharedgeneticsbetween pages 4-5, cheng2024sharedgeneticsbetween pages 5-7). Together with historical literature tying FN3K activity to erythrocyte deglycation, these genetic data support a role for the FN3K/FN3KRP region in hemoglobin glycation metrics (garg2025themolecularbasis pages 12-13).
- Cancer and redox: FN3K expression is elevated in some tumors and influences therapeutic resistance via redox/NRF2-linked pathways; reducing FN3K expression can resensitize RCC to sunitinib (iScience, 2024; URL above) (shrestha2023elucidatingtheunderstudied pages 65-71). Computational/experimental screens implicate clinically used drugs in modulating FN3K expression and NRF2 signaling in breast cancer cells (PLOS ONE, 2023; URL above) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).

Open questions and cautions
- While human structures now clarify substrate recognition, quantification of in-cell substrate scope (protein targets, free vs protein-bound selectivity) and NAD binding constants remain to be defined. The VEGFR2 interaction requires definitive demonstration of direct deglycation (iScience 2024) (shrestha2023elucidatingtheunderstudied pages 65-71). Genetic associations near FN3K/FN3KRP influencing HbA1c are strong, but causal mechanisms (e.g., effects on erythrocyte glycation dynamics vs erythropoiesis) need further resolution (Open Targets; 2025) (OpenTargets Search: -FN3K).

References (URLs and dates)
- Shrestha et al., A redox-active switch in fructosamine-3-kinases. Science Signaling. Jul 14, 2020. URL: https://doi.org/10.1126/scisignal.aax6313 (shrestha2020aredoxactiveswitch pages 1-2).
- Garg et al., The molecular basis of human FN3K mediated phosphorylation of glycated substrates. Nature Communications. Jan 6, 2025. URL: https://doi.org/10.1038/s41467-025-56207-z (includes PDB 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13).
- Shrestha et al., Multi-omics reveals new links between FN3K and core metabolic pathways. NPJ Systems Biology & Applications. Jun 6, 2024. URL: https://doi.org/10.1038/s41540-024-00390-0 (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71, shrestha2023elucidatingtheunderstudied pages 17-22).
- Beeraka et al., Screening FN3K inhibitors; modulation of NRF2 signaling. PLOS ONE. Nov 1, 2023. URL: https://doi.org/10.1371/journal.pone.0283705 (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).
- Bai et al., Amiloride reduces FN3K expression to restore sunitinib sensitivity in RCC. iScience. Jun 18, 2024. URL: https://doi.org/10.1016/j.isci.2024.109997 (shrestha2023elucidatingtheunderstudied pages 65-71).
- De Decker et al., Enzymatic deglycation of damaged skin by FN3K and FAOD. International Journal of Molecular Sciences. May 15, 2023. URL: https://doi.org/10.3390/ijms24108981 (decker2023enzymaticdeglycationof pages 4-7).
- Matlack et al., Ancestral protein reconstruction reveals mechanisms of FN3K substrate specificity. bioRxiv. Jul 30, 2025. URL: https://doi.org/10.1101/2025.07.30.667714 (supports FN3K vs FN3KRP substrate distinctions) (matlack2025ancestralproteinreconstruction pages 15-18, matlack2025ancestralproteinreconstruction pages 12-15).
- Open Targets Platform (accessed 2025): FN3K/FN3KRP genetic associations with HbA1c measurement and related traits. URL: https://platform.opentargets.org (OpenTargets Search: -FN3K).
- Additional identity and localization notes: CRISPR-KO metabolomics and mentions of erythrocyte/serum presence (2023–2024 analyses) (shrestha2023elucidatingtheunderstudied pages 45-51, shrestha2024multiomicsrevealsnew pages 1-3).

Conclusion
Human FN3K (Q9H479) is a kinase-like deglycation enzyme that phosphorylates protein-bound fructosamines to promote deglycation, is regulated by a conserved redox disulfide switch, and likely interfaces with mitochondrial/NAD-linked metabolism. Recent human structures now enable rational inhibitor design. Genetic associations implicate the FN3K/FN3KRP locus in HbA1c variation. Early ex vivo applications (skin) and oncology findings (RCC sensitivity) suggest translational potential, while key mechanistic questions—physiologic substrates, NAD binding parameters, and pathway wiring—remain active areas of research (shrestha2020aredoxactiveswitch pages 1-2, garg2025themolecularbasis pages 12-13, shrestha2024multiomicsrevealsnew pages 1-3, OpenTargets Search: -FN3K, decker2023enzymaticdeglycationof pages 4-7, shrestha2023elucidatingtheunderstudied pages 65-71, beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).

References

1. (garg2025themolecularbasis pages 12-13): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 5 citations and is from a highest quality peer-reviewed journal.

2. (shrestha2020aredoxactiveswitch pages 1-2): Safal Shrestha, Samiksha Katiyar, Carlos E. Sanz-Rodriguez, Nolan R. Kemppinen, Hyun W. Kim, Renuka Kadirvelraj, Charalampos Panagos, Neda Keyhaninejad, Maxwell Colonna, Pradeep Chopra, Dominic P. Byrne, Geert J. Boons, Esther van der Knaap, Patrick A. Eyers, Arthur S. Edison, Zachary A. Wood, and Natarajan Kannan. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. This article has 24 citations and is from a domain leading peer-reviewed journal.

3. (garg2025themolecularbasis pages 1-2): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 5 citations and is from a highest quality peer-reviewed journal.

4. (shrestha2024multiomicsrevealsnew pages 1-3): Safal Shrestha, Rahil Taujale, Samiksha Katiyar, and Natarajan Kannan. Multi-omics reveals new links between fructosamine-3-kinase (fn3k) and core metabolic pathways. NPJ Systems Biology and Applications, Jun 2024. URL: https://doi.org/10.1038/s41540-024-00390-0, doi:10.1038/s41540-024-00390-0. This article has 3 citations and is from a poor quality or predatory journal.

5. (shrestha2023elucidatingtheunderstudied pages 65-71): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and …. Unknown journal, 2023.

6. (matlack2025ancestralproteinreconstruction pages 15-18): Jenet K. Matlack, Robert E. Miner, Jameela Lokhandwala, and Jennifer M. Binning. Ancestral protein reconstruction reveals the mechanism of substrate specificity in fn3k-mediated deglycation. bioRxiv, Jul 2025. URL: https://doi.org/10.1101/2025.07.30.667714, doi:10.1101/2025.07.30.667714. This article has 0 citations and is from a poor quality or predatory journal.

7. (shrestha2023elucidatingtheunderstudied pages 90-95): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and …. Unknown journal, 2023.

8. (shrestha2023elucidatingtheunderstudied pages 17-22): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and …. Unknown journal, 2023.

9. (shrestha2023elucidatingtheunderstudied pages 45-51): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and …. Unknown journal, 2023.

10. (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2): Narasimha M. Beeraka, Jin Zhang, Subhankar Mandal, Hemanth Vikram P. R., Junqi Liu, Namitha B. M., Di Zhao, Prashanth Vishwanath, Gurupadayya B. M., and Ruitai Fan. Screening fructosamine-3-kinase (fn3k) inhibitors, a deglycating enzyme of oncogenic nrf2: human fn3k homology modelling, docking and molecular dynamics simulations. PLOS ONE, 18:e0283705, Nov 2023. URL: https://doi.org/10.1371/journal.pone.0283705, doi:10.1371/journal.pone.0283705. This article has 10 citations and is from a peer-reviewed journal.

11. (decker2023enzymaticdeglycationof pages 4-7): Ignace De Decker, Margo Notebaert, Marijn M. Speeckaert, Karel E. Y. Claes, Phillip Blondeel, Elisabeth Van Aken, Jo Van Dorpe, Filip De Somer, Margaux Heintz, Stan Monstrey, and Joris R. Delanghe. Enzymatic deglycation of damaged skin by means of combined treatment of fructosamine-3-kinase and fructosyl-amino acid oxidase. International Journal of Molecular Sciences, 24:8981, May 2023. URL: https://doi.org/10.3390/ijms24108981, doi:10.3390/ijms24108981. This article has 5 citations and is from a poor quality or predatory journal.

12. (OpenTargets Search: -FN3K): Open Targets Query (-FN3K, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

13. (cheng2024sharedgeneticsbetween pages 4-5): Yuan-Fang Cheng, Cheng-Yi Yang, and Meng-Che Tsai. Shared genetics between age at menarche and type 2 diabetes mellitus: genome-wide genetic correlation study. Biomedicines, 12:157, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010157, doi:10.3390/biomedicines12010157. This article has 1 citations and is from a poor quality or predatory journal.

14. (cheng2024sharedgeneticsbetween pages 5-7): Yuan-Fang Cheng, Cheng-Yi Yang, and Meng-Che Tsai. Shared genetics between age at menarche and type 2 diabetes mellitus: genome-wide genetic correlation study. Biomedicines, 12:157, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010157, doi:10.3390/biomedicines12010157. This article has 1 citations and is from a poor quality or predatory journal.

15. (matlack2025ancestralproteinreconstruction pages 12-15): Jenet K. Matlack, Robert E. Miner, Jameela Lokhandwala, and Jennifer M. Binning. Ancestral protein reconstruction reveals the mechanism of substrate specificity in fn3k-mediated deglycation. bioRxiv, Jul 2025. URL: https://doi.org/10.1101/2025.07.30.667714, doi:10.1101/2025.07.30.667714. This article has 0 citations and is from a poor quality or predatory journal.

## Citations

1. garg2025themolecularbasis pages 12-13
2. shrestha2020aredoxactiveswitch pages 1-2
3. shrestha2023elucidatingtheunderstudied pages 45-51
4. shrestha2023elucidatingtheunderstudied pages 65-71
5. decker2023enzymaticdeglycationof pages 4-7
6. garg2025themolecularbasis pages 1-2
7. shrestha2024multiomicsrevealsnew pages 1-3
8. matlack2025ancestralproteinreconstruction pages 15-18
9. shrestha2023elucidatingtheunderstudied pages 90-95
10. shrestha2023elucidatingtheunderstudied pages 17-22
11. cheng2024sharedgeneticsbetween pages 4-5
12. cheng2024sharedgeneticsbetween pages 5-7
13. matlack2025ancestralproteinreconstruction pages 12-15
14. https://doi.org/10.1126/scisignal.aax6313;
15. https://doi.org/10.1038/s41467-025-56207-z;
16. https://doi.org/10.1038/s41540-024-00390-0;
17. https://doi.org/10.1101/2025.07.30.667714;
18. https://doi.org/10.1371/journal.pone.0283705;
19. https://doi.org/10.1016/j.isci.2024.109997;
20. https://doi.org/10.3390/ijms24108981;
21. https://doi.org/10.3390/biomedicines12010157;
22. https://doi.org/10.1126/scisignal.aax6313
23. https://doi.org/10.1038/s41467-025-56207-z
24. https://doi.org/10.1038/s41540-024-00390-0
25. https://doi.org/10.1371/journal.pone.0283705
26. https://doi.org/10.1016/j.isci.2024.109997
27. https://doi.org/10.3390/ijms24108981
28. https://doi.org/10.1101/2025.07.30.667714
29. https://platform.opentargets.org
30. https://doi.org/10.1038/s41467-025-56207-z,
31. https://doi.org/10.1126/scisignal.aax6313,
32. https://doi.org/10.1038/s41540-024-00390-0,
33. https://doi.org/10.1101/2025.07.30.667714,
34. https://doi.org/10.1371/journal.pone.0283705,
35. https://doi.org/10.3390/ijms24108981,
36. https://doi.org/10.3390/biomedicines12010157,